Novel Betulin Derivatives as Antileishmanial Agents with Mode of Action Targeting Type IB DNA Topoisomerase
Open Access
- 12 July 2011
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 80 (4), 694-703
- https://doi.org/10.1124/mol.111.072785
Abstract
Toward developing antileishmanial agents with mode of action targeted to DNA topoisomerases of Leishmania donovani, we have synthesized a large number of derivatives of betulin. The compound, a natural triterpene isolated from the cork layer of Betula spp. plants exhibits several pharmacological properties. Three compounds (disuccinyl betulin, diglutaryl dihydrobetulin, and disuccinyl dihydrobetulin) inhibit growth of the parasite as well as relaxation activity of the enzyme type IB topoisomerase [Leishmania donovani topoisomerase I (LdTOP1LS)] of the parasite. Mechanistic studies suggest that these compounds interact with the enzyme in a reversible manner. The stoichiometry of these compounds binding to LdTOP1LS is 1:1 (mole/mole) with a dissociation constant on the order of ∼10−6 M. Unlike CPT, these compounds do not stabilize the cleavage complex; rather, they abrogate the covalent complex formation. In processive mode of relaxation assay condition, these compounds slow down the strand rotation event, which ultimately affects the relaxation of supercoiled DNA. It is noteworthy that these compounds reduce the intracellular parasite burden in macrophages infected with wild-type L. donovani as well as with sodium antimony gluconate resistant parasite (GE1). Taken together, our data suggest that these betulin derivatives can be exploited as potential drug candidates against threatening drug resistant leishmaniasis.Keywords
This publication has 37 references indexed in Scilit:
- Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropicaJournal of the European Academy of Dermatology and Venereology, 2010
- Lipsosomal Amphotericin B for Treatment of Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2010
- Leishmaniasis vaccine: Where are we today?Journal of Global Infectious Diseases, 2010
- Immunological perspectives of leishmaniasisJournal of Global Infectious Diseases, 2010
- Targeting DNA topoisomerase II in cancer chemotherapyNature Reviews Cancer, 2009
- An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I fromLeishmania donovaniby 3,3′-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzymeBiochemical Journal, 2007
- Development of miltefosine as an oral treatment for leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- ‘LeishMan’ topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovaniNucleic Acids Research, 2006
- Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovaniCell Death & Differentiation, 2004
- Reconstitution and functional characterization of the unusual bi‐subunit type I DNA topoisomerase from Leishmania donovaniFEBS Letters, 2004